Cargando…

Correction to: The role of PSA density in the MRI pathway for prostate cancer diagnostics

Detalles Bibliográficos
Autores principales:	Cash, Hannes, Schostak, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638079/ https://www.ncbi.nlm.nih.gov/pubmed/37012330 http://dx.doi.org/10.1038/s41391-023-00664-4

Ejemplares similares

The role of PSA density in the MRI pathway for prostate cancer diagnostics
por: Cash, Hannes, et al.
Publicado: (2022)

Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial
por: Pye, Hayley, et al.
Publicado: (2021)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI
por: Ma, Zengni, et al.
Publicado: (2023)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

Incidence of Histological Prostatitis and Its Correlation with PSA Density
por: Piovesan, Affonso Celso, et al.
Publicado: (2009)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
por: Morote, Juan, et al.
Publicado: (2022)

Performance of prostate health index and PSA density in a diverse biopsy‐naïve cohort with mpMRI for detecting significant prostate cancer
por: Carbunaru, Samuel, et al.
Publicado: (2021)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models
por: Stavrinides, Vasilis, et al.
Publicado: (2021)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
por: Akkaya, Hüseyin, et al.
Publicado: (2023)

Correction: Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI
por: Girometti, Rossano, et al.
Publicado: (2022)

Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer
por: Song, Wei, et al.
Publicado: (2022)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium
por: Song, Zi-Jian, et al.
Publicado: (2020)

Role of PSA Density and MRI in PSA Interpretation. Comment on Lumbreras et al. Variables Associated with False-Positive PSA Results: A Cohort Study with Real-World Data. Cancers 2023, 15, 261
por: Jue, Joshua S., et al.
Publicado: (2023)

Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model
por: Gentile, Francesco, et al.
Publicado: (2021)

Correction to: impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous (18)F-choline PET/MRI for prostate cancer
por: Muehlematter, Urs J., et al.
Publicado: (2018)

Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade
por: Venkatesan, Aradhana M., et al.
Publicado: (2021)

MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review
por: Regmi, Subodh K., et al.
Publicado: (2021)

Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461
por: von Eyben, Rie, et al.
Publicado: (2023)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways
por: Lophatananon, Artitaya, et al.
Publicado: (2023)

Follow-Up of Men Who Have Undergone Focal Therapy for Prostate Cancer with HIFU—A Real-World Experience
por: Mala, Katharina Sophie, et al.
Publicado: (2023)

Value of MRI to Improve Deep Learning Model That Identifies High-Grade Prostate Cancer. Comment on Gentile et al. Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model. Diagnostics 2021, 11, 335
por: Jue, Joshua S., et al.
Publicado: (2021)

Correction: Early biomarkers of extracapsular extension of prostate cancer using MRI-derived semantic features
por: Guerra, Adalgisa, et al.
Publicado: (2023)

Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial
por: Nam, Robert, et al.
Publicado: (2022)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study
por: Bruno, Salvatore M., et al.
Publicado: (2021)

Beyond PSA: The Role of Prostate Health Index (phi)
por: Ferro, Matteo, et al.
Publicado: (2020)

Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study
por: Pantelidou, Maria, et al.
Publicado: (2022)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

Diagnostic Efficacy of PSMA and PSCA mRNAs Combined to PSA in Prostate Cancer Patients
por: Mahmoud, Mustafa M, et al.
Publicado: (2023)

Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vmgagrmjvsg86bhgg6bq55spbj